Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D72.12Drug rash with eosinophilia and systemic symptoms syndrome

✓ Billable / specific

D72.12 is a valid, billable ICD-10-CM code for drug rash with eosinophilia and systemic symptoms syndrome. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2021 (effective October 1, 2020). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About D72.12

D72.12 is the ICD-10-CM diagnosis code for drug rash with eosinophilia and systemic symptoms syndrome. It belongs to category D72 (other disorders of white blood cells), block D70-D77 (other disorders of blood and blood-forming organs) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D72.1 (eosinophilia), D72.12 is specifically for drug rash with eosinophilia and systemic symptoms syndrome. Related codes cover unspecified (D72.10), hypereosinophilic syndrome [HES] (D72.11), in diseases classified elsewhere (D72.18) and other eosinophilia (D72.19).

Use an additional code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2021, effective October 1, 2020.

Coding notes

Applicable toConditions and synonyms classified to this code
  • DRESS syndrome
Use additional codeAdd a secondary code to fully describe the condition
  • code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)

Notes that apply from higher levels

Instructions written at a parent level also apply to D72.12.

› From D72.1 Eosinophilia
Excludes2
  • Löffler's syndrome (J82.89)
  • pulmonary eosinophilia (J82.-)
› From D72 Other disorders of white blood cells
Excludes1
Excludes2
  • neutropenia (D70)

Broader instructions also apply from Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.

Alphabetic index entries

2 entries

Terms in the official ICD-10-CM index that lead to D72.12.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2021 (effective 10/1/2020): Added
  • No changes since FY2021.

Common questions about D72.12

Is D72.12 billable?

Yes. D72.12 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D72.12 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict D72.12 as a principal diagnosis.

Is D72.12 a CC or MCC?

No. D72.12 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does D72.12 group to?

D72.12 is used in the MS-DRG v44.0 logic for MS-DRG 814 (Reticuloendothelial and Immunity Disorders with MCC), MS-DRG 815 (Reticuloendothelial and Immunity Disorders with CC) and MS-DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.